Fabtech Technologies Limited — Investor Meet, 03-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Fabtech Technologies Limited held an earnings conference call discussing Q1 FY27 results. Management highlighted a strong Q1 performance with a consolidated revenue of ₹74.98 Cr, up 10% YoY, and a significant turnaround to a net profit of ₹4.21 Cr from a net loss of ₹6.13 Cr in the prior year. EBITDA also saw a substantial recovery, reaching ₹7.41 Cr with a 9% margin. The company emphasized its EPC business's H2-weighted nature and expressed confidence in achieving its full-year organic growth guidance of 20-25%. Strategic diversification into markets like Saudi Arabia and Africa, coupled with margin improvements driven by a shift to higher-value markets, were key factors. The order book stood at over ₹900 Cr, with active inquiries exceeding ₹9,300 Cr. Upcoming acquisitions in Italy and Saudi Arabia are progressing, aiming to strengthen local execution capabilities and market reach.

The discussion covered revenue growth drivers, including stellar performance in Saudi Arabia and scaling in Africa, which offset headwinds in the UAE segment. Management detailed strategic investments in Saudi Arabia to build a local platform, enhancing eligibility for key infrastructure projects. The company's financial discipline was evident in reduced finance costs due to optimized working capital and IPO proceeds. Regarding the order book, visibility remains strong for the next two years, with active inquiries and hot leads indicating significant future potential. Management affirmed its focus on profitable growth, disciplined execution, and localized diversification to drive long-term stakeholder value.

In the Q&A, management addressed investor concerns about stock performance, attributing it to market sentiment beyond their control, while reaffirming their commitment to business growth and profitability. Receivables were explained as largely backed by LCs or CAD, with a portion related to standard retention periods and specific large Saudi contracts. The company outlined its long-term vision for growth in emerging pharmaceutical markets, driven by localization and strategic acquisitions. Management also clarified the nature of UAE weakness, attributing it to a shift towards high-tech facilities, and highlighted their ability to leverage UAE as a hub for showcasing diverse project capabilities. The order book's geographic split and repeat customer contributions were also discussed, alongside strategies to enhance investor communication and engagement. The company anticipates substantial market growth in the pharmaceutical emerging markets over the next decade.